Antibalder GHK-Cu + Minoxidil – 60 capsules (preorder) Product Information
Antibalder — GHK-Cu + Minoxidil oral research capsules, combining two of the most extensively cited hair-cycle-modulating molecules in the dermatology literature into a single research formulation. GHK-Cu (the copper tripeptide-1 complex) is one of only two bioactive peptides explicitly recommended in published trichology consensus reviews. Minoxidil is, by a wide margin, the most studied small molecule in male and female pattern hair-loss research: more than 40 controlled trials, three decades of post-marketing data, and a well-characterized mechanism centered on follicular vasodilation and ATP-sensitive K⁺-channel opening. Antibalder pairs them in fixed unit doses to enable structured experimental work on combined-pathway hair-cycle modulation. RESEARCH USE ONLY · Not for human or veterinary use. For laboratory and collector purposes only. Purity ≥ 99 % (HPLC, both actives) — third-party tested, CoA on file Form Research capsules Content GHK-Cu and minoxidil — fixed unit doses per capsule (see CoA) Total 60 capsules per bottle Packaging Sealed bottle with tamper-evident closure Storage Room temperature, protected from light, kept desiccated Active 1 GHK-Cu — Cu²⁺ tripeptide-1 complex; CAS 89030-95-5; MF C₁₄H₂₄CuN₆O₄; MW ≈ 403.92 g·mol⁻¹ Active 2 Minoxidil — CAS 38304-91-5; MF C₉H₁₅N₅O; MW ≈ 209.25 g·mol⁻¹ Synonyms Copper tripeptide-1; GHK; Lamorelin; Loniten (minoxidil) Research Overview GHK (glycyl-L-histidyl-L-lysine) is a tripeptide naturally present in human plasma at micromolar concentrations, where it forms a high-affinity 1:1 complex with copper(II) — the bioactive form, GHK-Cu [1]. The complex modulates more than 4,000 human genes (over a third of the human genome) according to Connectivity-Map analyses, with a clear bias toward tissue-remodeling, anti-inflammatory and anti-aging programs; in dermal papilla cells specifically, GHK-Cu upregulates VEGF, FGF-7 and noggin and prolongs anagen [1]. Minoxidil — originally developed as an antihypertensive — is the gold-standard topical and oral drug in pattern hair loss; its sulfate metabolite opens vascular ATP-sensitive K⁺ channels and dramatically upregulates VEGF in dermal papilla, prolonging anagen and shortening telogen [2,3]. Recent low-dose oral minoxidil literature has expanded the pharmacology beyond topical applications, with multiple controlled studies demonstrating efficacy at doses orders of magnitude below antihypertensive thresholds [3]. Antibalder enables researchers to study the combined effect of these two convergent vascular-and-trophic pathways in a single fixed-ratio formulation. Primary Research Areas Hair cycle and dermal-papilla biology — the two best-characterized small-molecule/peptide tools for prolonging anagen and rescuing miniaturized follicles in research models [1,2]. VEGF / vascular research in skin — both actives independently upregulate dermal-papilla VEGF, providing a clean two-pathway design for vascular-mediated trichogenesis studies [1,2]. Wound healing and tissue remodeling — GHK-Cu has a long literature in skin wound healing, collagen organization and matrix metalloproteinase modulation [1]. ATP-sensitive K⁺ channel pharmacology — minoxidil sulfate is the canonical opener of K-ATP channels in vascular smooth muscle and dermal papilla cells [2]. Anti-inflammatory and anti-aging gene programs — GHK-Cu reproducibly resets Connectivity-Map signatures associated with cellular senescence and inflammaging [1]. References Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–746.
